Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 1997

View Archived Issues

EntreMed: Q3 1997 highlights

Olpadronate associated with improvement in osteogenesis imperfecta

Myriad Genetics and Bayer join forces to develop dementia and depression therapies

Cantab: Q3 1997 highlights

Microcide: Q3 1997 highlights

Clinical trial demonstrates efficacy of NPS-R-568 in hyperparathyroidism

Affymetrix: Q3 1997 highlights

Pharmacia & Upjohn: Q3 1997 highlights

GH secretagogues under development at Merck & Co.

Mitsui Norin discovers natural antiviral/antitumor agent

New triazole antifungals from Pfizer

Lilly claims antithrombotic diamides

Takeda reports novel carbapenems

Brain GABA receptor ligands prepared at Neurogen

DCK analogues with potent and selective anti-HIV activity

Role of complement in mast cell-dependent natural immunity

Favorable results obtained in pediatric study of Neuprex

Phase I trial of multiple-dose IDEC-C2B8 in NHL

New NK1 antagonist from Novartis

Six-month trial of lamivudine for chronic hepatitis B

Role of substance P in PTH secretion described

FDA advisory committee recommends approval of Rocephin for AOM

Doxil/Caelyx evaluated in phase II for advanced breast cancer

NK3 antagonist demonstrates intestinal antiinflammatory activity

Palatin receives FDA clearance to start LeuTech clinical trials

Antifungal activity of KP-103 under evaluation

Gel formulation of diclofenac and hyaluronan effective in aphthous ulcer pain

Novartis launches once-monthly formulation of Sandostatin

Combivir recommended for approval in Europe

Development of new quinolone from Toyama advances

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...